Core Insights - Scott+Scott Attorneys at Law LLP is investigating Alvotech for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3] - Alvotech develops and manufactures biosimilar medicines, focusing on therapeutic areas such as autoimmune, eye, bone disorders, and cancer [2] - On November 2, 2025, Alvotech received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA) for AVT05, a biosimilar candidate to Simponi®, indicating deficiencies that must be resolved before approval [3] - Following the FDA's announcement, Alvotech's stock price dropped approximately 34%, closing at $5.03 on November 3, 2025 [3]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Marex Group PLC for possible violations of federal securities laws and unlawful business practices, encouraging affected investors to reach out for legal options [1][2]. Investigation Details - The investigation is prompted by a report from NINGI Research, which alleges that Marex has been involved in a multi-year accounting scheme, utilizing opaque off-balance-sheet entities and misleading disclosures to hide significant losses and inflate profits [6]. - The report claims that Marex's financial statements are unreliable, describing the company's financial structure as a "financial house of cards" [6]. Stock Impact - Following the release of the NINGI Research report, Marex's stock price dropped by $2.33, or 6.19%, closing at $35.31 per share on August 5, 2025 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Sensus Healthcare, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The investigation is focused on whether Sensus has engaged in any unlawful activities that may have affected its stockholders [1][2]. Financial Performance - On August 7, 2025, Sensus reported a second quarter GAAP earnings-per-share of -$0.06, missing estimates by $0.09 - Revenue for the same period was $7.3 million, reflecting a year-over-year decline of 20.7% and missing estimates by $2 million - The revenue decline was attributed to a lower number of units sold to a large customer, although there was some growth in recurring revenue from Fair Deal Agreements [6]. Stock Price Reaction - Following the financial results announcement, Sensus's stock price dropped by $1.89 per share, or 35.32%, closing at $3.46 per share on August 8, 2025 [6]. Next Steps for Investors - Investors who purchased Sensus shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their legal rights and potential claims [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation across the United States [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Avita Medical, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Avita has engaged in practices that may have harmed investors, particularly in light of recent financial disclosures [1][2]. Financial Performance - On August 7, 2025, Avita reported a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand in the first half of the year [6]. - The backlog was attributed to contractors from the Centers for Medicare & Medicaid Services failing to assign adequate pricing and timely adjudication of claims, leading to uncertainty among providers [6]. - Following this announcement, Avita's stock price fell by $1.13, or approximately 21%, from $5.38 to $4.25 per share [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against J.M. Smucker Company for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on the financial performance of Smucker, particularly following the acquisition of Hostess Brands for approximately $5.5 billion, which included $2.4 billion recorded as goodwill [6]. - Recent financial results have shown significant declines in net sales and substantial impairment charges, raising concerns about the company's business practices and financial health [6]. Financial Performance - On February 27, 2025, Smucker reported a Q3 2025 net sales decrease of 8% in the Sweet Baked Snacks segment, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [6]. - On June 10, 2025, the company announced a further decline of 14% in Q4 2025 net sales for the Sweet Baked Snacks segment, with an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [6]. - Following these announcements, Smucker's share price fell by $17.44, or approximately 15.59%, closing at $94.41 per share on June 10, 2025 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Abacus Global Management, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - A report by Morpheus Research on June 4, 2025, accused Abacus of being involved in a life settlements accounting scheme, leading to a stock price decline of over 21% [2]. Next Steps - Abacus shareholders who have suffered losses or have information regarding the claims are encouraged to contact Bragar Eagel & Squire for further assistance [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a law firm recognized nationally, representing investors in various complex litigations across state and federal courts [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Simulations Plus, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The law firm is reaching out to Simulations Plus stockholders who may have suffered losses and encourages them to discuss their legal rights [1][3]. Financial Performance - Simulations Plus reported third fiscal quarter sales of $20.4 million, missing the consensus estimate of $20.9 million [6]. - The company experienced a net loss of $67.3 million and a diluted loss per share of $3.35, which included a non-cash impairment charge of $77.2 million, compared to a net income of $3.1 million and diluted earnings per share of $0.15 for the same period in 2024 [6]. - The fiscal 2025 adjusted earnings guidance was revised down to $0.93 to $1.06 from a previous range of $1.07 to $1.20 [6]. Operational Changes - In June, Simulations Plus initiated a restructuring of its operations, which included workforce reductions and cost-cutting measures aimed at improving operational efficiency and reducing expenses [6]. Stock Market Reaction - Following the financial results announcement, Simulations Plus's stock price fell by $4.50 per share, or 25.76%, closing at $12.97 per share on July 15, 2025 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Barnes & Noble Education, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3]. Group 1: Investigation Details - The investigation is prompted by a delay in Barnes & Noble's annual report for the fiscal year ended May 3, 2025, due to an ongoing investigation into the recording of digital sales costs [3]. - Early findings suggest that Barnes & Noble may have overstated accounts receivable by up to $23 million and expects to report at least one material weakness related to manual journal entries [3]. Group 2: Market Reaction - Following the news of the investigation, Barnes & Noble's stock price fell by $2.36 per share, representing a decline of 21.02%, closing at $8.87 per share on July 21, 2025 [4]. Group 3: Legal Support - Investors who have suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for assistance [1][5].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against James Hardie Industries plc for possible violations of federal securities laws and unlawful business practices [2] - James Hardie reported a 29% decline in first-quarter profit for the period ending June 30, 2025, and projected lower-than-expected earnings for fiscal 2026 due to high borrowing costs [3] Financial Performance - The company experienced a significant drop in its American Depositary Receipt (ADR) price, which fell by $9.79 per ADR, or 34.44%, closing at $18.64 per ADR on August 20, 2025, following the announcement of its financial results [3] Legal Context - Investors who suffered losses from purchasing or acquiring James Hardie shares are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights [1][4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Marex Group PLC for possible violations of federal securities laws and unlawful business practices, following a report that raised serious concerns about the company's financial integrity [2][3]. Group 1: Investigation and Allegations - The law firm is encouraging investors who suffered losses in Marex to contact them to discuss their legal rights [1][4]. - NINGI Research published a report on August 5, 2025, claiming that Marex has been involved in a multi-year accounting scheme, utilizing opaque off-balance-sheet entities and misleading disclosures to hide significant losses and inflate profits [3]. - Following the release of the report, Marex's stock price dropped by $2.33, or 6.19%, closing at $35.31 per share [3]. Group 2: Company Background - Marex Group PLC is publicly traded on NASDAQ under the ticker MRX [2]. - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations [5].